HC Wainwright & Co. Initiates Coverage On Artelo Biosciences with Buy Rating, Announces Price Target of $4
HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Artelo Biosciences (NASDAQ:ARTL) with a Buy rating and announces Price Target of $4.
New Study Comparing Plant-Derived and Synthetic CBD Efficacy Opens Door to Exciting Medical Uses of Cannabidiol
Image Provided by Bill Oxford on Unsplash
EXCLUSIVE: Artelo Biosciences CEO, Greg Gorgas Now Interviewing On Benzinga’s Power Hour Show
Click To Tune In Here: https://www.youtube.com/watch?v=k922EWXuQ6k
Artelo Biosciences Q3 EPS $(0.10) Up From $(0.27) YoY
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.10) per share. This is a 62.96 percent increase over losses of $(0.27) per share from the same period last year.
New Cannabinoid-Based Drug Candidates from Artelo Biosciences Show Promise as Cancer and Mental Health Treatments; Key Data Due Before Year End
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Artelo Biosciences Highlights 2 Poster Presentations At 31st Annual International Cannabinoid Research Society Symposium, Jun. 22, 23
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today